latest news in companies
LuxUrban Report Separates Corporate Liabilities From Founder's Personal Finances
San Francisco, Sunday, 11 January 2026.
New filings argue LuxUrban’s financial collapse stems from systemic corporate risks, attempting to distinguish business exposure from the founder’s personal finances despite $98 million in guarantees.
Corcept Therapeutics Faces Market Selloff and Legal Probes Following FDA Rejection of Relacorilant
San Francisco, Friday, 9 January 2026.
Corcept Therapeutics (NASDAQ: CORT) is under intense pressure after the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, a treatment for hypertension caused by hypercortisolism. The regulatory rejection, announced on December 31, 2025, precipitated a massive 50% collapse in share value, effectively erasing $3.6 billion in market capitalization. While the FDA acknowledged some positive trial data, it concluded that additional evidence is required to establish the drug’s effectiveness. Consequently, the company now faces a wave of investigations from shareholder rights law firms, including Hagens Berman and Scott+Scott. These inquiries focus on whether management overstated relacorilant’s clinical efficacy and the commercial prospects of its hypercortisolism business to investors. Analysts have subsequently downgraded price targets, casting doubt on Corcept’s ability to meet its projected revenue goals within the previously stated timeframe.
Apogee Enterprises Under Investigation After Stock Plunges Seventeen Percent
San Diego, Friday, 9 January 2026.
Apogee Enterprises faces a federal securities investigation after its stock plummeted 17% on January 7, 2026. The sharp decline coincided with missed revenue targets and the sudden resignation of CFO Matthew Osberg.
Aquestive Therapeutics Faces Legal Scrutiny After FDA Flags Deficiencies in Anaphylm Application
Atlanta, Friday, 9 January 2026.
Aquestive Therapeutics is under investigation for potential securities violations following a nearly 40% stock plunge on January 9, 2026. The sharp decline occurred after the FDA identified deficiencies in the application for Anaphylm, the company’s severe allergy treatment, effectively stalling labeling discussions. With the critical January 31 approval deadline looming, multiple law firms are now examining whether the company misled investors regarding the drug’s regulatory viability.
Lawsuit Alleges EmblemHealth Blocked Mental Health Access Through Inaccurate Directories
New York, Friday, 9 January 2026.
The complaint accuses the insurer of inflating networks with unavailable providers—listing one psychiatrist 29 times—effectively denying New York City employees access to covered mental health treatment.
